Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Patent questio

<< Previous

Bullboard Posts

Next >>

Comment by TriumphSpitSixon Apr 23, 2021 5:13pm

161 Views

Post# 33059707

RE:Patent questio

Correct. All IP would be transferred to Pfizer in acquisition transaction, so the patent would be theirs. No generics could be sold until the patent term expires.

Qtrlbder wrote:
let's say if Pfizer acquired ATE and use H2S to create a new form of Aspirin. Will this be a new patent for Pfizer and none of the other pharma can make this new aspirin as a generic drug?

<< Previous

Bullboard Posts

Next >>

How a truck transportation and logistics company leverages acquisitions and technology